




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>C07C 401/00, A61K 31/59</b>	<b>A1</b>	(11) International Publication Number: <b>WO 91/00855</b> (43) International Publication Date: 24 January 1991 (24.01.91)
(21) International Application Number: PCT/DK90/00168 (22) International Filing Date: 4 July 1990 (04.07.90) (30) Priority data: 8915770.5                      10 July 1989 (10.07.89)                      GB (71) Applicant (for all designated States except US): LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØV-ENS KEMISKE FABRIK PRODUKTIONSAKTIE-SELSKAB) [DK/DK]; Industriparken 55, DK-2750 Ballerup (DK). (72) Inventors; and (75) Inventors/Applicants (for US only) : BINDERUP, Ernst, Torndal [DK/DK]; Ludvig Hegners Allé 8A, DK-2630 Tåstrup (DK). CALVERLEY, Martin, John [GB/DK]; Oktobervej 61, DK-2730 Herlev (DK).		(74) Agent: KRISTENSEN, P., Rydahl; Leo Pharmaceutical Products, Industriparken 55, DK-2750 Ballerup (DK). (81) Designated States: AT (European patent), AU, BB, BE (European patent), BG, BR, CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, MW, NL (European patent), NO, RO, SD, SE (European patent), SU, US. Published With international search report.

(54) Title: NOVEL VITAMIN D ANALOGUES



## (57) Abstract

The present invention relates to compounds of formula (I), in which formula  $n$  is 2 or 3,  $m$  is 0 or an integer from 1-4;  $R^1$  and  $R^2$  (which may be the same or different) stand for hydrogen or  $C_1$ - $C_8$ -hydrocarbyl, hydrocarbyl indicating the residue after removal of a hydrogen atom from a straight, branched or cyclic saturated or unsaturated hydrocarbon, or taken together with the carbon bearing the hydroxyl group (starred in formula (I)),  $R^1$  and  $R^2$  can form a saturated or unsaturated  $C_3$ - $C_8$  carboxylic ring; in addition,  $R^1$  and/or  $R^2$  and/or one of the  $m$  carbons designated by the "°" may be optionally substituted with one or more chlorine or fluorine atom(s); and finally one of the carbons designated "°" may optionally be substituted by one or two  $C_1$ - $C_2$  alkyl group(s); and derivatives of the compounds of formula (I) in which one or more hydroxy have been transformed into -O-acyl or O-glycosyl or phosphate ester groups; such masked groups being hydrolyzable *in vivo*. The present compounds find use in both the human and veterinary practice in the treatment and prophylaxis of autoimmune diseases (including diabetes mellitus), hypertension, acne, alopecia, skin ageing, imbalance in the immune system, inflammatory diseases such as rheumatoid arthritis and asthma as well as diseases characterized by abnormal cell differentiation and/or cell proliferation, such as e.g. psoriasis and cancer.

### DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

#### *FOR THE PURPOSES OF INFORMATION ONLY*


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

## NOVEL VITAMIN D ANALOGUES

This invention relates to a hitherto unknown class of compounds which shows antiinflammatory and immunomodulating effects as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells, including cancer cells and skin cells, to pharmaceutical preparations containing these compounds, to dosage units of such preparations, and to their use in the treatment and prophylaxis of a number of disease states including diabetes mellitus, hypertension, acne, alopecia, skin ageing, imbalance in the immune system, inflammatory diseases such as rheumatoid arthritis and asthma as well as diseases characterized by abnormal cell differentiation and/or cell proliferation such as e.g. psoriasis and cancer.

The compounds of the invention constitute a novel class of vitamin D analogues and are represented by the general formula I



in which formula (and also throughout the remainder of this disclosure), n is 2 or 3, m is 0 or an integer from 1 - 4; R<sup>1</sup> and R<sup>2</sup> (which may be the same or different) stand for hydrogen or C<sub>1</sub>-C<sub>8</sub>-hydrocarbyl, or, taken together with the

carbon bearing the hydroxyl group (starred in formula I),  $R^1$  and  $R^2$  can form a saturated or unsaturated  $C_3-C_8$  carbocyclic ring. In addition,  $R^1$  and/or  $R^2$  and/or one of the  $m$  carbons designated by the "\*" may be optionally substituted with one or more chlorine or fluorine atom(s); and finally one of the carbons designated "\*" may optionally be substituted by one or two  $C_1-C_2$  alkyl group(s).

In the context of this invention, the expression hydrocarbyl radical indicates the residue after removal of a hydrogen atom from a straight, branched or cyclic saturated or unsaturated hydrocarbon.

Examples of  $R^1$  and  $R^2$  when taken separately include (apart from hydrogen), but are not limited to, methyl, trifluoromethyl, ethyl, vinyl, normal-, iso- and cyclopropyl, and 1-methylvinyl.

Examples of  $R^1$  and  $R^2$  when taken together include di-, tri-, tetra- and penta-methylene.

As can be seen from formula I, the compounds of the invention include diastereoisomeric forms (e.g. E or Z configuration of a side chain double bond; R or S configuration at C-20 and at the starred carbon atom depending on the meanings of  $R^1$  and  $R^2$ ). The invention covers all these diastereoisomers in pure form and also mixtures of diastereoisomers. It should be noted, however, that our investigations indicate a notable difference in activity between the stereoisomeric forms. In addition, derivatives of I in which one or more of the hydroxy groups are masked as groups which can be reconverted to hydroxy groups in vivo are also within the scope of the invention ("bioreversible derivatives or pro-drugs of I").

The term "bioreversible derivatives or prodrugs of I" includes, but is not limited to, derivatives of the compounds of formula I in which one or more hydroxy groups have been transformed into -O-acyl or -O-glycosyl or phosphate ester groups, such masked groups being hydrolyzable in vivo.

Also within the scope of this disclosure is another type of prodrug of I in which the hydroxyl group at the

**SUBSTITUTE SHEET**

starred carbon atom is replaced by a hydrogen atom. These compounds are relatively inactive in vitro, but are converted to active compounds of formula I by enzymatic hydroxylation after administration to the patient.

5 It has recently been shown that  $1\alpha,25$ -dihydroxy-vitamin  $D_3$  ( $1,25(OH)_2D_3$ ) influences the effects and/or production of interleukins (Immunol. Lett. 17, 361-366 (1988)), indicating the potential use of this compound in the treatment of diseases characterized by a dysfunction of  
10 the immune system, e.g. autoimmune diseases, host versus graft reactions, and rejection of transplants or other conditions characterized by an abnormal interleukin-1 production, e.g. inflammatory diseases such as rheumatoid arthritis and asthma.

15 It has also been shown that  $1,25(OH)_2D_3$  is able to stimulate the differentiation of cells and inhibit excessive cell proliferation (Abe, E. et al, Proc. Natl. Acad. Sci., U.S.A. 78, 4990-4994 (1981)), and it has been suggested that this compound might be useful in the  
20 treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis.

Also, the use of  $1,25(OH)_2D_3$ , or its pro-drug  $1\alpha$ -OH- $D_3$ , for the treatment of hypertension (Lind, L. et al, Acta Med. Scand. 222, 423-427 (1987)) and diabetes mellitus (Inomata, S. et al, Bone Mineral 1, 187-192 (1986)) has been suggested. Another indication for  $1,25(OH)_2D_3$  is suggested by the recent observation of an association between hereditary vitamin D resistance and  
25 alopecia: treatment with  $1,25(OH)_2D_3$  may promote hair growth (Lancet, March 4, 1989, p. 478). Finally, the fact that topical application of  $1,25(OH)_2D_3$  reduces the size of sebaceous glands in the ears of male Syrian hamsters suggests that this compound might be useful for the  
30 treatment of acne (Malloy, V.L. et al., the Tricontinental Meeting for Investigative Dermatology, Washington, 1989).

However, the therapeutic possibilities in such indications of  $1,25(OH)_2D_3$  are severely limited by the well

known potent effect of this hormone on calcium metabolism; elevated blood concentrations will rapidly give rise to hypercalcemia. Thus, this compound and its potent synthetic analogues are not completely satisfactory for use as drugs  
5 in the treatment of e.g. psoriasis, leukemia or immune diseases which may require continuous administration of the drug in relatively high doses.

A number of vitamin D analogues have recently been described which show some degree of selectivity in favour  
10 of the cell differentiation inducing/cell proliferation inhibiting activity as compared with the effect on calcium metabolism.

Thus, the vitamin D<sub>3</sub> analogue, MC 903, containing a 22,23-double bond, a 24-hydroxy group and in which the  
15 carbon atoms 25,26 and 27 are incorporated in a three membered ring, is a potent inducer of cell differentiation and inhibitor of cell proliferation which shows only moderate activity on calcium metabolism in vivo (Binderup, L. and Bramm, E., Biochemical Pharmacology 37, 889-895  
20 (1988)). However, this selectivity is not paralleled by in vitro studies, which show that MC 903 binds equally well as 1,25(OH)<sub>2</sub>D<sub>3</sub> to the intestinal vitamin D receptor. It may therefore be that the low in vivo activity on calcium metabolism of MC 903 is due to a rapid metabolism of the  
25 compound, thus limiting the potential of this compound for systemic use.

24-Homo-1,25-dihydroxyvitamin D<sub>3</sub> and 26-homo-1,25-dihydroxyvitamin D<sub>3</sub> (together with their 22,23-didehydro-analogues) (Ostrem, V.K.; Tanaka, Y.; Prah, J.; DeLuca,  
30 H.F.; and Ikekawa, N.; Proc. Natl. Acad. Sci. USA 84, 2610-14 (1987)) have been claimed to have the same binding affinity as 1,25(OH)<sub>2</sub>D<sub>3</sub> to both the rat and chicken intestinal receptor and the receptor in a human myeloid leukemia cell line (HL-60), and yet to be 10-fold more  
35 potent than 1,25(OH)<sub>2</sub>D<sub>3</sub> in inducing differentiation of HL-60 cells in vitro. In vivo, these compounds are respectively "significantly less potent" and "more potent" than 1,25(OH)<sub>2</sub>D<sub>3</sub> in calcium metabolism assessments.

26,27-Dimethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> has been synthesized, but the published information regarding its biological activities is contradictory. (Sai, H.; Takatsuto, S.; Hara, N.; and Ikekawa, N.; Chem. Pharm. Bull. 33, 878-881 (1985) and Ikekawa, N.; Eguchi, T.; Hara, N.; Takatsuto, S.; Honda, A.; Mori, Y.; and Otomo, S.; Chem. Pharm. Bull. 35, 4362-4365 (1987)). The closely related 26,27-diethyl-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> is also reported by these authors; in this case as having "almost no vitamin D activity" (i.e. calcium metabolism effects) while being 10-fold more potent than 1,25(OH)<sub>2</sub>D<sub>3</sub> in inducing cell differentiation.

The fact that there are only small structural differences between the above compounds indicates that the present state of knowledge does not allow prediction of the structure of vitamin D analogues which will show a favourable degree of selectivity, as reflected by a higher cell differentiating activity in vitro compared to the binding affinity for intestinal vitamin D receptor in vitro. Furthermore, the matter is complicated by the observation that receptor binding affinities in vitro are not always paralleled by in vivo studies, probably reflecting a pharmacokinetic difference between the compounds.

The compounds of the present invention are distinguished structurally from all vitamin D analogues which have been reported to have potent effects on cell differentiation/proliferation by the presence of a conjugated diene or triene moiety in the side chain.

Corresponding compounds which have a saturated side chain or an isolated double bond (22,23-didehydro-derivatives) have been disclosed in international patent application No. PCT/DK89/00079, international filing date 7th April, 1989 and (for one pair of examples) in the Ostrem et al, reference discussed above, but none of these disclosures suggest methods for the incorporation of a conjugated polyene system into the side chain. Our synthetic studies have now opened up general routes to such

polyene systems, and it has been surprisingly found that this type of functionality has an advantageous biological significance. Thus a particular compound of formula I, when compared to the corresponding compound in which all, or all but the 22,23-double bond, are saturated, is observed to show one or more of the following advantages:-

- (a) more potent effects on cell differentiation/proliferation;
- (b) a greater selectivity in favour of the potent effects on cell differentiation/proliferation contra the effects on calcium metabolism;
- (c) more potent effects on the production and action of interleukins;
- (d) a greater selectivity in favour of the effects on interleukin production and action contra the effects on calcium metabolism.

An additional advantage conferred on the compounds I by the presence of the polyene moiety results from the more restricted conformational freedom of the side chain: the compounds I of the present invention are more readily obtained crystalline than the corresponding side chain saturated or partially saturated analogues.

The compounds of the invention are therefore especially suited for both local and systemic treatment and prophylaxis of human and veterinary disorders which are characterized by 1) abnormal cell proliferation and/or cell differentiation, such as certain dermatological disorders including psoriasis and certain cancer forms, 2) an imbalance in the immune system, e.g in autoimmune diseases, including diabetes mellitus, host versus graft reaction, and rejection of transplants; and additionally for the treatment of inflammatory diseases, such as rheumatoid arthritis and asthma. Acne, alopecia, skin ageing (including photoageing), and hypertension are other conditions which may be treated with the compounds of the invention.

The present compounds may be used in combination with other pharmaceuticals. In the prevention of graft rejection and graft versus host reaction, a treatment with




the present compounds may advantageously be combined with e.g. a cyclosporin treatment.

Compounds I can be prepared from the vitamin D-derived aldehyde 1j [M.J. Calverley, Tetrahedron 43, 4609 (1987)] or 1k, which may be obtained by triplet-sensitized photoisomerization of 1j, optionally via the compounds 2 or 3 (Scheme 1). Schemes 2 to 4 illustrate reactions for the conversion of these key intermediates to compounds I in which n, m, R<sup>1</sup> and R<sup>2</sup> have various meanings.

The exemplified key intermediates of types 2 and 3 are listed in Table 1.


In the Schemes, the following abbreviations are used:



In the Notes to Schemes, appropriate aqueous work-up steps are implicit. The absolute configuration at C-20 can be either R or S. For explanation of the expression "side chain fragment", see following text.

30

35

Scheme 1Notes to Scheme 1

20

1j  $\rightarrow$  1k:

h $\nu$  - anthracene (toluene or CH<sub>2</sub>Cl<sub>2</sub> containing trace Et<sub>3</sub>N).

1  $\rightarrow$  2:

Ph<sub>3</sub><sup>+</sup>P<sup>-</sup>CH-(CH=CH)<sub>x-1</sub>-CO<sub>2</sub>Me (heat in solvent e.g. toluene or CHCl<sub>3</sub>).

25 2  $\rightarrow$  3:

(i) *i*-Bu<sub>2</sub>AlH (THF); (ii) pyridinium dichromate (CH<sub>2</sub>Cl<sub>2</sub>).

3 (x=1)  $\rightarrow$  2 (x=3): Ph<sub>3</sub><sup>+</sup>P<sup>-</sup>CH-(CH=CH)-CO<sub>2</sub>Me (heat in solvent e.g. CHCl<sub>3</sub>).

1  $\rightarrow$  3 (x=2)

30


3(x=1)  $\rightarrow$  3(x=3)

$$\begin{array}{c} \text{O} \\ || \\ (\text{EtO})_2\text{P} \end{array} \text{-CH=CH-CH=CH-N} \begin{array}{c} \diagup \\ \diagdown \end{array} \begin{array}{c} \diagup \\ \diagdown \end{array} \text{C}_6\text{H}_{11}$$
 , LiN(Pr<sup>i</sup>)<sub>2</sub>;

(ii) hydrolysis during flash chromatography

35


### Scheme 2



### Notes to Scheme 2


- 20 a.  $R^1MgBr$  ( $R^1MgI$ ) or  $R^1Li$  (THF);  
b. Metallated derivative or ylide ( $A'$ ) from side chain  
fragment A (anhydrous solvent or phase transfer  
conditions);  
25 c.  $NaBH_4-CeCl_3$  (THF-MeOH).  
d. for  $R^1 = R^2 = H$ :  $i-Bu_2AlH$  (THF).

10

Scheme 3Notes to Scheme 3

- 20 a. (i) Metallated derivative (B') of side chain fragment B (THF); (ii) Optional derivatisation of the intermediate alkoxide (Y=M) or the isolated Y=H compound;
- b. Reductive elimination mediated by e.g. Na-Hg [for Y=H, MeC(O)-, PhC(O)- or MeS(O<sub>2</sub>)-]

25

Scheme 4

30

35

- a  $\left\{ \begin{array}{l} \text{II (m = 0) or V} \\ \text{II (m = 0) or V} \end{array} \right.$
- b  $\left\{ \begin{array}{l} \text{II (m = 0) or V} \\ \text{I} \end{array} \right.$
- $\text{R} = \underline{j}$   
 $\text{R} = \underline{k}$   
 $\text{R}^3 = \text{H}$

Notes to Scheme 4

$R^3$  = H or alcohol protective group



- a. anthracene -  $h\nu$  (toluene or  $CH_2Cl_2$  containing trace  
 5  $Et_3N$ );  
 b. (i)  $n-Bu_4N^+F^-$  (THF) or HF ( $MeCN-H_2O$ );  
 (ii) any necessary reaction (sequence) for deprotecting  
 $OR^3 \rightarrow OH$ .

10

A key step in some of the syntheses as described is the reaction with an intermediate (of type A' or B') which is obtained by treatment of a side chain fragment of type  
 15 A or B respectively) either by conversion to an organo-metallic agent or to an ylide, as appropriate.

All these types of reactions are well known in the art of carbon-carbon bond formation in synthetic organic chemistry.

20 In general, the side chain fragments have the structure:



with the following meanings (the following standard abbreviations are used throughout this disclosure: Et = ethyl; Hep = heptyl; Me = methyl; Ph = phenyl; Pr = propyl  
 30 THP = tetrahydro-4H-pyran-2-yl; THF = tetrahydrofuran; Ts *p*-toluenesulphonyl; DMF = N,N-dimethylformamide):

For type A,  $Z = Ph_3P^+-CH_2-$  or  $Z = Q_2P(O)-CH_2-$ , where Q = methoxy, ethoxy or phenyl, and the corresponding A' has  
 $Z = Ph_3P^+-CH^-$  or  $Q_2P(O)-CHM-$  (M = metal e.g. Li).

35 For type B,  $Z = PhS(O_2)-CH_2-$ , and the corresponding B' has  $Z = PhS(O_2)-CHM-$ , where M = metal, e.g. Li.

$R^3$  is optionally hydrogen or an alcohol protective group such as tri(loweralkyl)silyl or THP. In the case

where  $R^3 = H$  in B, then  $R^5 = M$  (M = metal, e.g. XMg or Li) in the derived B'.

Fragments of type A, A' or B are known compounds or readily available as described for example in international patent application No. PCT/DK89/00079, international filing date 7th April, 1989, and British patent application No. 8914963.7, filing date 29th June, 1989. Some Examples are listed in Tables 2 and 3.

Some of these side chain fragments are converted (see Preparations and Examples) to the appropriate compounds I via the intermediates indicated in the Schemes. The intermediates are specified in Table 4 and the exemplified compounds I in Table 5.

Specific compounds I are also available by special reactions. For example, the compound 112 (Table 5) is obtained by isomerisation of MC 903 by treatment with trifluoroacetic anhydride, followed by saponification.

Table 1: Exemplified Key intermediates prepared from Compounds 1a or 1b (Scheme 1)

Compound Number	Formula	
	x	Configuration of side chain polyene *
2aj	1	<u>E</u>
2ak	1	<u>E</u>
2aj	2	<u>E</u> , <u>E</u>
2aj; isomer A	3	<u>E</u> , <u>E</u> , <u>E</u>
2aj; isomer B	3	<u>E</u> , <u>Z</u> , <u>E</u>
3aj	1	<u>E</u>
2bj	2	<u>E</u> , <u>E</u>
2ak	3	<u>E</u> , <u>E</u> , <u>E</u>

\* Reading from left to right.

**Table 2: Some Specific Side Chain Fragments (Type A and A')**  
 $[Z-C(O)R^2]$

Compound Number <sup>+</sup>	$R^2$ <span style="float: right;"><math>Z</math></span>
5            4	$-CHMe_2$ $Ph_3^+PCH^-$
5 $y=1$	$-\overline{CH(CH_2)_y}CH_2$ $Ph_3^+PCH^-$
5 $y=2$	
5 $y=3$	
5 $y=4$	
10           6	$-\overline{CCl-CH_2-}CH_2$ $Ph_3^+PCH^-$
7	$-\overline{CF-CH_2-}CH_2$ $(EtO)_2P(O)CH_2$
8	$-CMe_3$ $Ph_3^+PCH^-$
9	$-CHEt_2$ $Ph_3^+PCH^-$
10	$-CH(n-Pr)_2$ $Ph_3^+PCH^-$

15    <sup>+</sup> As referred to in the Preparations

20

25

30

**Table 3: Some Specific Side Chain Fragments (Type B)**  

$$[\text{PhS}(\text{O}_2)\text{CH}_2-(^\circ\text{CH}_2)_m-\text{C}(\text{R}^1)(\text{R}^2)\text{OR}^3]$$

Compound Number	† m	Formula		
		R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
5 11	1	Me	Me	H
12	1	Et	Et	H
13	1	-(CH <sub>2</sub> ) <sub>2</sub> -		THP
14	2	Et	Et	H
15 15	3	Me	Me	H
10 16	4	Me	Me	H
17 ++	1 (CH(Me))	Me	Me	H
18 **	1 (CH(Me))	Me	Me	H

+ As referred to in the Preparations

15 ++ S-Form

\*\* R-Form

† Unsubstituted CH<sub>2</sub> unless otherwise indicated by specifying an alternative meaning of "(°CH<sub>2</sub>)".

20

25

30



Table 4: Compounds of Schemes 2-4 which are Intermediates in the Preparation of Compounds I of Scheme 4

	Com- pound Number (R=j or k)	Type	Scheme	n	m <sup>†</sup>	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	Config- uration of the side chain poly- ene *	Con- fig- ura- tion at C-20
5										
10	101j	III	2	2	-	-	$\overline{\text{CHCH}_2\text{CH}_2}$	-	<u>E,E</u>	<u>R</u>
	102j	II	2	} 2	-	H	$\overline{\text{CHCH}_2\text{CH}_2}$	-	<u>E,E</u>	<u>R</u>
	103j	II	2		-	H	$\overline{\text{CHCH}_2\text{CH}_2}$	-	<u>E,E</u>	<u>R</u>
	102k	II	4	} 2	-	H	$\overline{\text{CHCH}_2\text{CH}_2}$	-	<u>E,E</u>	<u>R</u>
	103k	II	4		-	H	$\overline{\text{CHCH}_2\text{CH}_2}$	-	<u>E,E</u>	<u>R</u>
15	104j	II	2	2	-	Me	Me	-	<u>E,E</u>	<u>R</u>
	104k	II	4	2	-	Me	Me	H	<u>E,E</u>	<u>R</u>
	105j	II	2	2	-	Et	Et	-	<u>E,E</u>	<u>R</u>
	105k	II	4	2	-	Et	Et	H	<u>E,E</u>	<u>R</u>
	106j	II	2	3	-	Me	Me	-	<u>E,E,E</u>	<u>R</u>
20	107j	V	3	2	1	Me	Me	H	<u>E,E</u>	<u>R</u>
	107k	II	4	2	1	Me	Me	H	<u>E,E</u>	<u>R</u>
	113j	II	2	2	-	Me	Me	-	<u>E,E</u>	<u>S</u>
	113k	II	4	2	-	Me	Me	H	<u>E,E</u>	<u>S</u>
	114j	II	2	2	-	Et	Et	-	<u>E,E</u>	<u>S</u>
25	114k	II	4	2	-	Et	Et	H	<u>E,E</u>	<u>S</u>
	117j	II	2	2	-	H	H	-	<u>E,E</u>	<u>S</u>
	117k	II	4	2	-	H	H	H	<u>E,E</u>	<u>S</u>
	119j	II	2	2	-	Pr	Pr	-	<u>E,E</u>	<u>R</u>
30	119k	II	4	2	-	Pr	Pr	H	<u>E,E</u>	<u>R</u>

Table 4 (continued):

5	Com- pound Number (R=j or k)	Type	Scheme	n	m <sup>†</sup>	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	Config- uration of the side chain poly- ene *	Con- fig- ura- tion at C-20
10	121j	II	2	2	-	H	H	-	<u>E</u> , <u>E</u>	<u>R</u>
	121k	II	4	2	-	H	H	H	<u>E</u> , <u>E</u>	<u>R</u>
	123k	II	2	1	-	H	H	-	<u>E</u>	<u>R</u>
	124k	II	2	3	-	Me	Me	-	<u>E</u> , <u>E</u> , <u>E</u>	<u>R</u>
	126k	II	2	3	-	Et	Et	-	<u>E</u> , <u>E</u> , <u>E</u>	<u>R</u>
15	128k	II	2	3	-	H	H	-	<u>E</u> , <u>E</u> , <u>E</u>	<u>R</u>

† Note as for Table 3

\* Reading from left to right

NB Where identical descriptions for two numbered compounds are given (e.g. 102j and 103j) the compounds are distinguished only in their configuration at the starred carbon atom. These configurations give rise to two series of compounds, referred to as "isomer A" and "isomer B" in the Preparations and Examples.

Table 5: Exemplified Compounds I

5	Compound Number	m <sup>+</sup>	n	R <sup>1</sup>	R <sup>2</sup>	Configuration of side chain polyene*	Configuration at C-20
10	108 } 109 }	0	2	H	$\overline{\text{CHCH}_2\text{CH}_2}$	<u>E</u> , <u>E</u>	<u>R</u>
	110	0	2	Me	Me	<u>E</u> , <u>E</u>	<u>R</u>
	111	0	2	Et	Et	<u>E</u> , <u>E</u>	<u>R</u>
	112	1	2	H	H	<u>E</u> , <u>E</u>	<u>R</u>
	115	0	2	Me	Me	<u>E</u> , <u>E</u>	<u>S</u>
	116	0	2	Et	Et	<u>E</u> , <u>E</u>	<u>S</u>
	118	0	2	H	H	<u>E</u> , <u>E</u>	<u>S</u>
	120	0	2	Pr	Pr	<u>E</u> , <u>E</u>	<u>R</u>
	122	0	2	H	H	<u>E</u> , <u>E</u>	<u>R</u>
	125	0	3	Me	Me	<u>E</u> , <u>E</u> , <u>E</u>	<u>R</u>
20	127	0	3	Et	Et	<u>E</u> , <u>E</u> , <u>E</u>	<u>R</u>
	129	0	3	H	H	<u>E</u> , <u>E</u> , <u>E</u>	<u>R</u>
	130	1	2	H	H	<u>E</u> , <u>E</u>	<u>S</u>
	131 } 132 }	0	2	H	$\overline{\text{CHCH}_2\text{CH}_2}$	<u>E</u> , <u>E</u>	<u>S</u>
	133	1	2	Me	Me	<u>E</u> , <u>E</u>	<u>R</u>
	134	1	2	Me	Me	<u>E</u> , <u>E</u>	<u>S</u>
	135	1	2	Et	Et	<u>E</u> , <u>E</u>	<u>S</u>
	136	1	2	Et	Et	<u>E</u> , <u>E</u>	<u>R</u>
	137-38	1(CH(Me))	2	Me	Me	<u>E</u> , <u>E</u>	<u>R</u>
	139-40	1(CH(Me))	2	Me	Me	<u>E</u> , <u>E</u>	<u>S</u>

30 Notes as for Table 4

Parallel reactions can be used to convert other side chain fragments to the corresponding compounds I.

In cases where  $R^1 \neq R^2$  in compounds II or V, the isomers can be separated and the configuration at the  
5 starred carbon atom can be inverted or equilibrated at this stage by application of standard reactions.

The synthesis of the prodrugs of compounds I which lack the side chain hydroxyl (at the starred carbon atom) may follow the route of Scheme 3, using the appropriate  
10 side chain fragment of structure  $Z-(^*CH_2)_m-CH(R^1)(R^2)$ .

The present compounds are intended for use in pharmaceutical compositions which are useful in the treatment of human and veterinary disorders as described above.

The amount required of a compound of formula I (hereinafter referred to as the active ingredient) for therapeutic effect will, of course, vary both with the particular compound, the disease state which is to be treated, the route of administration and the mammal under treatment. The compounds of the invention can be administered by the  
15 parenteral, intra-articular, enteral or topical routes. They are well absorbed when given enterally and this is the preferred form of administration in the treatment of systemic disorders.

Conveniently, the active ingredient comprises from  
25 0.1 - 100  $\mu\text{g/g}$  for topical formulations and 0.05 - 100  $\mu\text{g/g}$  for oral and parenteral formulations.

By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient as a physically and chemically stable unit dose  
30 comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents or carriers.

The formulations, both for veterinary and for human medical use, of the present invention comprise an active  
35 ingredient in association with a pharmaceutically acceptable carrier therefore and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the

formulations and not deleterious to the recipient thereof.

The formulations include e.g. those in a form suitable for oral, rectal, parenteral (including transdermal, subcutaneous, intramuscular and intravenous), intra-  
5 articular and topical administration.

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association  
10 with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the  
15 product into the desired formulation.

Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form  
20 of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid; or in the form of an oil-in-water emulsion or a water-in-oil emulsion.

A tablet may be made by compressing or moulding the  
25 active ingredient optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed by a binder, lubricant, inert diluent, surface active  
30 or dispersing agent. Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered active ingredient and suitable carrier moistened with an inert liquid diluent.

Formulations for rectal administration may be in the  
35 form of a suppository incorporating the active ingredient and a carrier such as cocoa butter, or in the form of an enema.

Formulations suitable for parenteral administration

conveniently comprise a sterile oily or aqueous preparation of the active ingredient which is preferably isotonic with the blood of the recipient.

Formulations suitable for intra-articular administration may be in the form of a sterile aqueous preparation of the active ingredient which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to present the active ingredient for both intra-articular and ophthalmic administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops; or as sprays.

For asthma treatment, inhalation of powder, self-propelling or spray formulations, dispensed with a spray can, a nebulizer or an atomizer can be used. The formulations, when dispensed, preferably have a particle size in the range of 10 to 100  $\mu$ .

Such formulations are most preferably in the form of a finely comminuted powder for pulmonary administration from a powder inhalation device or self-propelling powder-dispensing formulations. In the case of self-propelling solution and spray formulations, the effect may be achieved either by choice of a valve having the desired spray characteristics (i.e. being capable of producing a spray having the desired particle size) or by incorporating the active ingredient as a suspended powder in controlled particle size. These self-propelling formulations may be either powder-dispensing formulations or formulations dispensing the active ingredient as droplets of a solution or suspension.

Self-propelling powder-dispensing formulations preferably comprise dispersed particles of solid active ingredients, and a liquid propellant having a boiling point below 18°C at atmospheric pressure. The liquid propellant

may be any propellant known to be suitable for medicinal administration and may comprise one or more C<sub>1</sub>-C<sub>6</sub>-alkyl hydrocarbons or halogenated C<sub>1</sub>-C<sub>6</sub>-alkyl hydrocarbons or mixtures thereof; chlorinated and flourinated C<sub>1</sub>-C<sub>6</sub>-alkyl hydrocarbons are especially preferred. Generally, the propellant constitutes 45 to 99.9% w/w of the formulation whilst the active ingredient constitutes 1 ppm to 0.1% w/w, of the formulation.

In addition to the aforementioned ingredients, the formulations of this invention may include one or more additional ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.

The compositions may further contain other therapeutically active compounds usually applied in the treatment of the above mentioned pathological conditions.

The present invention further concerns a method for treating patients suffering from one of the above pathological conditions, said method consisting of administering to a patient in need of treatment an effective amount of one or more compounds of formula I, alone or in combination with one or more other therapeutically active compounds usually applied in the treatment of said pathological conditions. The treatment with the present compounds and/or with further therapeutically active compounds may be simultaneous or with intervals.

In the treatment of systemic disorders daily doses of from 0.01-100 µg, preferably from 0.025-50 µg, of a compound of formula I are administered. In the topical treatment of dermatological disorders, ointments, creams or lotions containing from 0.1-100 µg/g, and preferably from 0.5-10 µg/g, of a compound of formula I are administered. The oral compositions are formulated, preferably as tablets, capsules, or drops, containing from 0.01-100 µg, preferably from 0.025-50 µg, of a compound of formula I, per dosage unit.

The invention will now be further described in the

following non-limiting Preparations and Examples:

### Preparations and Examples

#### General

5       The compounds referred to in the Preparations and Examples are to be identified by number or letter with the corresponding formulae in the Schemes and/or Tables. Ultra-violet spectra ( $\lambda$ ) were measured for solutions in 96% ethanol. For nuclear magnetic resonance spectra chemical  
10 shift values ( $\delta$ ) are quoted in p.p.m. for deuterio-chloroform solutions relative to internal tetramethylsilane ( $\delta = 0$ ) or chloroform ( $\delta = 7.25$ ). The value for a multiplet, either defined (doublet (d), triplet (t), quartet (q)) or not (m) at the approximate mid point is given  
15 unless a range is quoted (s = singlet, b = broad). Coupling constants ( $J$ ) are given in Hertz, and are sometimes approximated to the nearest unit.

      Ether is diethyl ether, and was dried over sodium. THF was dried over sodium-benzophenone. Petroleum ether  
20 refers to the pentane fraction. Brine is saturated sodium chloride solution. Organic solutions were dried over dried magnesium sulphate and concentrated on a rotary evaporator at water aspirator pressure.

#### 25       Preparation 1       Compound 1ak

      A mixture of anthracene (0.10 g), triethylamine (20 mg), and the compound 1aj (0.20 g) in toluene (15 ml), stirred under an atmosphere of nitrogen in a Pyrex flask immersed in a water bath at 20°C, was illuminated with  
30 radiation from a high pressure Hg lamp (type: Hanau TQ 718Z2) for 30 minutes. The reaction mixture was filtered and concentrated in vacuo to give a residue. This was purified by chromatography (30 g silica gel, using 5% ether in petroleum ether as eluant) to give 1ak;  $\delta$  (300 MHz) 0.05  
35 (12H, bs), 0.56 (3H, s), 0.86 (18H, s), 1.12 (3H, d,  $J$  7), 1.15-2.05 (13H, m), 2.20 (1H, dd), 2.35 (1H, m), 2.43 (1H, m), 2.81 (1H, bd), 4.18 (1H, m), 4.36 (1H, m), 4.84 (1H, m), 5.16 (1H, m), 6.01 (1H, d,  $J$  11), 6.21 (1H, d,  $J$  11)



and 9.57 (1H, d,  $\underline{J}$  3).

Preparation 2: Compound 2aj (x = 1)

A stirred solution of 1aj (3.9 g), and methoxy-  
5 carbonylmethylene-triphenylphosphorane (4.6 g) in toluene  
(40 ml) was heated under reflux for 3 hours. The reaction  
mixture was cooled, filtered, and concentrated in vacuo.  
Purification of the residue by chromatography (200 g silica  
gel; 5% ether in petroleum ether as eluant) followed by  
10 recrystallization from ether-methanol gave 2aj (x=1), as  
needles, m.p. 129-130°C,  $\delta$  (300 MHz) 0.05 (12H, bs), 0.56  
(3H, s), 0.86 (9H, s), 0.89 (9H, s), 1.09 (3H, d,  $\underline{J}$  6.6),  
1.1-2.1 (13H, m), 2.28 (2H, m), 2.54 (1H, dd), 2.87 (1H,  
dd), 3.71 (13H, s), 4.21 (1H, m), 4.52 (1H, m), 4.94 (1H,  
15 bs), 4.98 (1H, bs), 5.75 (1H, d,  $\underline{J}$  15.5), 5.81 (1H, d,  $\underline{J}$   
11.5), 6.43 (1H, d,  $\underline{J}$  11.5), 6.84 (1H, dd,  $\underline{J}$  15.5 and  
9.0).

Preparation 3: Compound 2ak (x = 1)

20 The compound was prepared using the procedure of  
Preparation 2, but using 1ak as starting material instead  
of 1aj. The product was not obtained crystalline after this  
chromatographic purification,  $\delta$  (300 MHz) in agreement with  
assigned structure.

25

Procedure 1      Reduction of Compound 2 or 3 to  
the Corresponding Compound II  
(Scheme 2)

To a stirred solution of 2 or 3 (5 mmol) in dry THF  
30 (25 ml) at -70°C under N<sub>2</sub> was added di-isobutylaluminium  
hydride (1 M solution in hexanes, 15 ml for compound 2; 8  
ml for compound 3) dropwise. After stirring for 30 minutes,  
methanol (3 ml) was added dropwise, and the reaction  
mixture was allowed to warm up to room temperature. EtOAc  
35 and water were added, and after stirring for an additional  
30 minutes, the organic phase was separated, washed with  
brine, dried and concentrated to give II, which was option-  
ally purified by chromatography and/or recrystallisation.

Preparation 4: 1(S),3(R)-bis-tert-butyl-  
dimethyl-  
silyloxy-20(R)-(3'-hydroxyprop-1'(E)-  
-enyl)-9,10-secopregna-5(E),7(E),  
10(19)-triene

5       The compound was prepared using Procedure 1 in which  
the starting material was compound 2aj (x=1). The crude  
product was of sufficient purity for use as starting mater-  
ial in Preparation 5. An analytical sample was obtained by  
recrystallisation from ether-MeOH; m.p. 118-120°C;  $\delta$  (300  
10 MHz) 0.05 (12H, bs), 0.55 (3H, s), 0.86 (9H, s), 0.89 (9H,  
s), 1.04 (3H, d,  $J$  6), 1.10-2.20 (15H, m), 2.29 (1H, d),  
2.54 (1H, dd), 2.87 (1H, m), 4.06 (2H, m), 4.21 (1H, m),  
4.52 (1H, m), 4.93 (1H, bs), 4.98 (1H, bs), 5.56 (2H, m),  
5.82 (1H, d,  $J$  11.5), 6.44 (1H, d,  $J$  11.5).

15

Preparation 5: Compound 3aj (x = 1)

Pyridinium dichromate (0.5 g) was added at room  
temperature to a stirred solution of the compound from  
Preparation 4 (0.53 g) in dichloromethane (10 ml). After  
20 stirring for 3 hours the mixture was diluted with ether and  
filtered. The filtrate was concentrated in vacuo and  
purified by chromatography (silica gel, hexane:ether 4:1 as  
eluant) to give 3aj (x=1) which crystallized on treatment  
with methanol. M.p.: 101-103°C;  $\delta$  (300 MHz) 0.06 (12H, m),  
25 0.59 (3H, s), 0.86 (9H, s), 0.89 (9H, s), 1.15 (3H, d,  $J$   
6.6), 1.20-2.10 (13H, m), 2.30 (1H, bd), 2.42 (1H, m), 2.55  
(1H, dd), 2.89 (1H, m), 4.21 (1H, m), 4.53 (1H, m), 4.94  
(1H, m), 4.98 (1H, m), 5.82 (1H, d,  $J$  11.4), 6.06 (1H, dd,  
 $J$  15.6 and 7.8), 6.44 (1H, d,  $J$  11.4), 6.71 (1H, dd,  $J$  15.6  
30 and 8.8), 9.48 (1H, d,  $J$  7.8).

Preparation 6: Compound 2aj (x = 2)

A mixture of 1aj (4.56 g), 3-(methoxycarbonyl)-2-  
-propenyl-1-idene-triphenylphosphorane (3.03 g) and  
35 alcohol-free chloroform (12 ml) was heated at 62°C with  
stirring under  $N_2$  while part of the chloroform was  
evaporated in vacuo. The mixture was kept at 62°C  
overnight, cooled and partitioned between ether and water.

The organic layer was dried and evaporated in vacuo. The resulting oil was purified by chromatography (silica gel, hexane-ether 97:3 as eluant) to give an oil which crystallized from ether/methanol. M.p.: 99-101°C;  $\lambda_{\max} =$   
 5 268 nm ( $\epsilon = 52372$ );  $\delta$  (300 MHz) 0.05 (12H, m), 0.56 (3H, s), 0.85 (9H, s), 0.89 (9H, s), 1.07 (3H, d,  $J$  6.69), 1.17-2.10 (13H, m), 2.25 (2H, m), 2.55 (1H, dd), 2.87 (1H, m), 3.73 (3H, s), 4.21 (1H, m), 4.52 (1H, m), 4.94 (1H, m), 4.98 (1H, m), 5.78 (1H, d,  $J$  15.3), 5.81 (1H, d,  $J$  11.4),  
 10 6.05 (2H, m), 6.44 (1H, d,  $J$  11.4), 7.24 (1H, dd).

Preparation 7: Compound 2aj (x = 3) Isomers A and B

A mixture of 3aj (x=1) (1 g), 3-(methoxycarbonyl)-2-propenyl-1-idene-triphenylphosphorane (1.26 g) and  
 15 alcohol-free chloroform (3 ml) was heated with stirring at 62°C while part of the chloroform was evaporated in vacuo. After 2 hours at 62°C the mixture was cooled and partitioned between ether and water. The organic layer was dried, concentrated and purified by chromatography (silica  
 20 gel, hexane-ether 9:1 as eluant). The first eluted title compound was isomer B;  $\delta$  (300 MHz) 0.06 (12H, m), 0.58 (3H, s), 0.86 (9H, s), 0.89 (9H, s), 1.08 (3H, d,  $J$  6,6) 1.17-2.35 (15H, m), 2.58 (1H, dd), 2.88 (1H, m), 3.75 (3H, s), 4.21 (1H, m), 4.53 (1H, m), 4.94 (1H, m), 4.98 (1H, m),  
 25 5.82 (3H, m), 5.98 (1H, t,  $J$  11.2), 6.26 (1H, t,  $J$  11.2), 6.45 (1H, d,  $J$  11.3), 6.57 (1H, dd), 7.75 (1H, m). The second eluted title compound was isomer A;  $\delta$  (300 MHz) 0.05 (12H, m), 0.56 (3H, s), 0.86 (9H, s), 0.89 (9H, s), 1.07 (3H, d,  $J$  6,6), 1.15-2.35 (15H, m), 2.55 (1H, dd),  
 30 2.87 (1H, m), 3.73 (3H, s), 4.21 (1H, m), 4.52 (1H, m), 4.93 (1H, m), 4.98 (1H, m), 5.81 (3H, m), 6.07 (1H, dd), 6.20 (1H, dd), 6.48 (2H, m), 7.29 (1H, dd).

Procedure 2

35

Reaction of Compound 3 with side chain fragment A' ( $Z = \text{Ph}_3\text{P}^{\oplus}-\text{CH}^{\ominus}$ ) to give Compound III (Scheme 2)

A stirred mixture of 3 and a molar excess of A' in toluene (5-10 ml per gram 1) was heated under reflux under

an N<sub>2</sub> atmosphere until a reasonable or complete conversion of 3 was obtained (4 to 16 hours). After cooling, the mixture was filtered, and the filtrate concentrated and purified by chromatography (5 - 20% ether in hexane or  
5 petroleum ether for the examples of Table 2) to give III.

Preparation 8: Compound 101j

Using the method of Procedure 2, a mixture of 3aj (x=1) (0.6 g) and cyclopropylcarbonylmethylenetriphenyl-  
10 phosphorane (5a) (0.86 g) and toluene (4 ml) was stirred at 110°C for 4 hours. After cooling to room temperature and filtration, the filtrate was concentrated in vacuo and purified by chromatography (silica gel, hexane-ether 85:5 as eluant) to give 101j as an oil which crystallized from  
15 methanol. M.p.: 106-108°C;  $\lambda_{\max}$  279.2 nm ( $\epsilon$  = 50220);  $\delta$  (300 MHz) 0.05 (12H, m), 0.56 (3H, s), 0.86 (9H, s), 0.89 (9H, s), 0.80-0.95 (2H, m), 1.00-1.15 (2H, m), 1.08 (3H, d,  $J$  6.5), 1.17-2.35 (16H, m), 2.55 (1H, dd), 2.88 (1H, m), 4.21 (1H, m), 4.53 (1H, m), 4.93 (1H, m), 4.98 (1H, m),  
20 5.81 (1H, d,  $J$  11.4), 6.12 (3H, m), 6.44 (1H, d,  $J$  11.4), 7.18 (1H, dd).

Procedure 3

Reduction of Compound III  
to Compound II ( $R^1 = H$ ) (Scheme 2)

25 Sodium borohydride (0.29 g) was added to an ice-cooled, stirred solution of III (2.5 g) in tetrahydrofuran (8 ml) and 0.4 M CeCl<sub>3</sub>·7H<sub>2</sub>O in ethanol (11.5 ml). Methanol (6 ml) was added over 10 minutes, and after stirring for a further 20 minutes the mixture was parti-  
30 tioned between ethyl acetate and water. The organic layer was washed with water, dried and concentrated in vacuo. The residue was purified by chromatography to give the compound II.

35 Preparation 9: Compounds 102j and 103j

Using the method of Procedure 3 (101j as starting material), two isomers were isolated by chromatography (3% acetone in toluene as eluant). First eluted isomer was

102j;  $\delta$  (300 MHz) 0.05 (12H, m), 0.20-0.40 (2H, m), 0.56 (3H, s), 0.45-0.60 (2H, m), 0.86 (9H, s), 0.89 (9H, s), 1.05 (3H, d,  $\underline{J}$  6.6), 0.70-2.35 (17H, m), 2.56 (1H, dd), 2.87 (1H, m), 3.48 (1H, t), 4.21 (1H, m), 4.53 (1H, m), 4.93 (1H, m), 4.98 (1H, m), 5.56 (1H, dd,  $\underline{J}$  15 and 8.6), 5.65 (1H, dd,  $\underline{J}$  15 and 6.6), 5.81 (1H, d,  $\underline{J}$  11.4), 5.97 (1H, dd,  $\underline{J}$  15 and 10.4), 6.17 (1H, dd,  $\underline{J}$  15 and 10.4), 6.45 (1H, d,  $\underline{J}$  11.4).

Second eluted isomer was 103j;  $\delta$  (300 MHz) 0.05 (12H, m), 0.20-0.40 (2H, m), 0.56 (3H, s), 0.44-0.65 (2H, m), 0.86 (9H, s), 0.89 (9H, s), 1.05 (3H, d,  $\underline{J}$  6.6), 0.70-2.35 (17H, m), 2.56 (1H, dd), 2.87 (1H, m), 3.49 (1H, t), 4.21 (1H, m), 4.53 (1H, m), 4.94 (1H, m), 4.98 (1H, m), 5.57 (1H, dd,  $\underline{J}$  15 and 8.6), 5.66 (1H, dd,  $\underline{J}$  15 and 6.4), 5.81 (1H, d,  $\underline{J}$  11.4), 5.97 (1H, dd,  $\underline{J}$  15 and 10.4), 6.19 (1H, dd,  $\underline{J}$  15 and 10.4), 6.45 (1H, d,  $\underline{J}$  11.4).

#### Procedure 4

#### Reaction of Compound 2 or 3 with $R^1Li$ to give Compound II (Scheme 2)

Alkyl-lithium (in ether, 3 molar equivalents for compound 2; 1.5 molar equivalent for compound 3) was added dropwise at  $-45^\circ\text{C}$  to a stirred solution of compound 2 or 3 (0.16 g) in dry THF (5 ml). After a further 50 minutes at  $-45^\circ\text{C}$  the mixture was partitioned between ether and water. The organic layer was washed with brine, dried, and concentrated. The residue was purified by chromatography (silica gel) to give II.

#### Preparation 10 Compound 104j

The compound was prepared using procedure 4 in which the alkyl-lithium was methyl-lithium (1.5 M) and the starting material was 2aj ( $x=2$ ). (Eluant: hexane-ether; 85:15). 104j  $\delta$  (300 MHz) 0.06 (12H, m), 0.56 (3H, s), 0.87 (9H, s), 0.90 (9H, s), 1.05 (3H, d,  $\underline{J}$  6.6), 1.33 (6H, s), 1.15-2.35 (16H, m), 2.56 (1H, dd), 2.87 (1H, m), 4.21 (1H, m), 4.53 (1H, m), 4.94 (1H, m), 4.98 (1H, m), 5.56 (1H, dd,  $\underline{J}$  15 and 8.6), 5.70 (1H, d,  $\underline{J}$  15.3), 5.81 (1H, d,  $\underline{J}$  11.4), 5.95 (1H, dd,  $\underline{J}$  15 and 10.3), 6.15 (1H, dd,  $\underline{J}$  15 and 10.3),

6.45 (1H, d,  $J$  11.4).

Preparation 11 Compound 105j

The compound was prepared using procedure 4 in which  
5 the alkyl-lithium was ethyl-lithium (1.5 M) and the  
starting material was 2aj ( $x=2$ ). (Eluant: hexane-ether;  
85:15). The compound crystallized from MeOH; m.p.: 84-85°C,  
 $\lambda_{\text{max}}$  232 nm ( $\epsilon = 37350$ ) and 269.5 nm ( $\epsilon = 26900$ ); 105j  $\delta$   
(300 MHz) 0.06 (12H, m), 0.56 (3H, s), 0.86 (9H, s), 0.89  
10 (9H, s), 0.86 (6H, t), 1.05 (3H, d,  $J$  6.6), 1.20-2.20 (19H,  
m), 2.30 (1H, bd), 2.56 (1H, dd), 2.87 (1H, m), 4.21 (1H,  
m), 4.53 (1H, m), 4.94 (1H, m), 4.98 (1H, m), 5.52 (1H, dd,  
 $J$  15.3), 5.54 (1H, dd,  $J$  15 and 8.6), 5.82 (1H, d,  $J$  11.4),  
5.97 (1H, dd,  $J$  15 and 10.3), 6.15 (1H, dd,  $J$  15 and 10.3),  
15 6.45 (1H, d,  $J$  11.4).

Preparation 12 Compound 106j

The compound was prepared using procedure 4 in which  
the alkyl-lithium was methyl-lithium (1.5 M) and the  
20 starting material was 2aj ( $x=3$ ) isomer A. (Eluant:  
hexane-ether; 85:15). 106j  $\delta$  (300 MHz) in agreement with  
structure.

Procedure 5 Preparation of Compounds V from  
25 Aldehyde (3) and Side Chain  
Fragment B (Scheme 3)

A solution of lithium di-iso-propylamide (0.4 M in  
THF-hexanes, 3:1) was added dropwise via a syringe (10  
minutes) to a solution of the side chain fragment B in dry  
30 THF (8 ml), stirred at -25°C under nitrogen. The resulting  
yellow solution was then cooled to -40°C, and a solution of  
the aldehyde (3) (2 mmol) in dry THF (8 ml) was added  
dropwise (5 minutes). After stirring for 30 minutes,  
benzoyl chloride (0.6 ml) was added dropwise, and the  
35 mixture was allowed to warm to 0°C for a further 30  
minutes. The reaction mixture was treated with ether (10  
ml) and water (1 ml) and partitioned between ethyl acetate  
(100 ml) and water (50 ml). The organic layer was washed

with brine, dried, and concentrated in vacuo to give a crude oil containing compound IV ( $Y = \text{PhC(O)}$ ) as a mixture of diastereoisomers. This was dissolved in ethyl acetate (5 ml) and diluted with methanol (50 ml, saturated with and  
5 containing suspended disodium hydrogen phosphate). To the ice-cooled mixture was added sodium amalgam (ca. 5% Na, 15 g), and the reaction mixture was stirred at 5°C under nitrogen for 15 hours. The mixture was then partitioned between ethyl acetate (200 ml) and water (200 ml)  
10 (decanting from the mercury), and the organic layer was washed with brine, dried and concentrated in vacuo. Purification of the residue by chromatography gave V.

Preparation 13 Compound 107j

15 This compound was prepared using Procedure 5 [aldehyde 3aj ( $x=1$ ) as starting material] in which the side chain fragment B was compound 11 (0.55 g) and 12 ml of the lithium di-iso-propylamide solution was used. The intermediate IV has  $R^3 = \text{OH}$ . The chromatography was performed on  
20 150 g silica gel using 10% ethyl acetate in petroleum ether as eluant. 107j;  $\delta$  0.05 (6H, bs), 0.56 (3H, s), 0.86 (9H, s), 0.89 (9H, s), 1.04 (3H, d, J 6), 1.1-2.70 (31H, m), 2.86 (1H, bd), 4.21 (1H, bs), 4.52 (1H, m), 4.94 (1H, bs), 4.98 (1H, bs), 5.45-5.65 (2H, m), 5.82 (1H, d, J 11),  
25 5.9-6.20 (2H, m), 6.44 (1H, d, J 11).

Procedure 6

Preparation of Compound II or V ( $R=k$ ) from the Corresponding Compound ( $R=j$ ) (Scheme 4)

30 A mixture of anthracene (0.10 g), triethylamine (20 mg), and the compound II or V ( $R=j$ ) (0.20 g) in dichloromethane (15 ml), stirred under an atmosphere of nitrogen in a Pyrex flask immersed in a water bath at 20°C, was illuminated with radiation from a high pressure Hg lamp  
35 (type: Hanau TQ 718Z2) for 30 minutes. The reaction mixture was filtered and concentrated in vacuo to give a residue. This was purified by chromatography (30 g silica gel) to give II or V ( $R=k$ ).

Preparation 14 Compound 102k

The compound was prepared using Procedure 6 in which starting material II was compound 102j. (Eluant: toluene-acetone, 97:3) 102k;  $\delta$  (300 MHz) 0.05 (12H, s), 0.18-0.40 (2H, m), 0.54 (3H, s), 0.45-0.65 (2H, m), 0.87 (18H, s), 1.04 (3H, d, J 7), 0.80-2.35 (16H, m), 2.44 (1H, dd), 2.80 (1H, bd), 2.58 (1H, m), 2.81 (1H, m), 3.49 (1H, t), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, d, J 2), 5.17 (1H, m), 5.61 (2H, m), 5.97 (2H, m), 6.18 (2H, m).

10

Preparation 15 Compound 103k

The compound was prepared using Procedure 6 in which starting material II was compound 103j. (Eluant: toluene-acetone, 97:3) 103k;  $\delta$  (300 MHz) 0.05 (12H, s), 0.18-0.40 (2H, m), 0.54 (3H, s), 0.45-0.65 (2H, m), 0.87 (18H, s), 1.04 (3H, d, J 7), 0.80-2.35 (16H, m), 2.44 (1H, dd), 2.80 (1H, bd), 2.81 (1H, m), 3.48 (1H, t), 4.16 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17 (1H, m), 5.61 (2H, m), 5.97 (2H, m), 6.18 (2H, m).

20

Preparation 16 Compound 104k

The compound was prepared using Procedure 6 in which starting material II was compound 104j. (Eluant: 25% ether in petroleum ether) 104k;  $\delta$  (300 MHz) 0.05 (12H, bs), 0.54 (3H, s), 0.88 (18H, s), 1.04 (3H, d, J 7), 1.32 (6H, s), 1.15-2.35 (16H, m, including 1.19 (6H, s)), 2.20 (1H, dd, J 13 and 7), 2.43 (1H, dd), 2.81 (1H, m), 4.18 (1H, m), 4.36 (1H, m), 4.86 (1H, bd), 5.17 (1H, dd), 5.55 (1H, dd), 5.69 (1H, d, J 15), 5.96 (2H, m), 6.22 (1H, d, J 11),

30

Preparation 17 Compound 105k

The compound was prepared using Procedure 6 in which starting material II was compound 105j. (Eluant: 25% ether in petroleum ether) 105k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.54 (3H, s), 0.85 (6H, t), 0.87 (18H, s), 1.04 (3H, d), 1.15-2.15 (19H, m), 2.20 (1H, dd), 2.43 (1H, dd), 2.82 (1H, bd), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.16 (1H, m), 5.51 (1H, d, J 15.3), 5.53 (1H, dd, J 15.0 and 8.7),

35



5.96 (1H, dd,  $\underline{J}$  15.0 and 13.0), 6.00 (1H, d), 6.14 (1H, dd,  $\underline{J}$  15.3 and 10.3), 6.22 (1H, d).

Preparation 18 Compound 2bj (x=2)

5 Using the method of Preparation 6 and by starting from 1bj (see British patent application No. 8914963.7) instead of 1aj, compound 2bj was obtained as an oil which crystallized from ether/methanol. M.p.: 108-110°C;  $\lambda_{\max}$  = 268 nm ( $\epsilon$  = 50887);  $\delta$  (300 MHz) 0.05 (12H, bs), 0.48 (3H, s), 0.86 (9H, s), 0.88 (9H, s), 0.97 (3H, d), 1.05-2.05  
10 (13H, m), 2.20 (1H, m), 2.30 (1H, bd), 2.53 (1H, dd), 2.84 (1H, bd), 3.72 (3H, s), 4.21 (1H, m), 4.51 (1H, m), 4.92 (1H, bs), 4.97 (1H, bs), 5.77 (1H, dd), 5.79 (1H, d), 5.95-6.15 (2H, m), 6.43 (1H, d), 7.25 1H, dd).

15

Preparation 19 Compound 113j

The compound was prepared using Procedure 4 in which the alkyl-lithium was methyl-lithium, and the starting material was 2bj (x = 2). 113j crystallized from MeOH;  $\lambda_{\max}$   
20 = 232 nm ( $\epsilon$  = 35228) and 269 nm ( $\epsilon$  = 25416);  $\delta$  (300 MHz) 0.05 (12H, m), 0.49 (3H, s), 0.85 (9H, s), 0.89 (9H, s), 0.94 (3H, d,  $\underline{J}$  6.6), 1.34 (6H, s), 1.00-2.15 (15H, m), 2.30 (1H, bd), 2.55 (1H, dd), 2.85 (1H, bd), 4.21 (1H, m), 4.52 (1H, m), 4.93 (1H, m), 4.98 (1H, m), 5.55 (1H, dd), 5.68  
25 (1H, d), 5.81 (1H, d,  $\underline{J}$  11.4), 5.91 (1H, dd), 6.15 (1H, dd), 6.45 (1H, d,  $\underline{J}$  11.4).

Preparation 20 Compound 113k

The compound was prepared using Procedure 6 in which  
30 starting material II was compound 113j. (Eluant: hexane-ether 80:20) 113k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.48 (3H, s), 0.85 (9H, s), 0.86 (9H, s), 0.93 (3H, d,  $\underline{J}$  6.6). 1.33 (6H, s), 1.00-2.15 (15H, m), 2.20 (1H, dd), 2.43 (1H, dd), 2.80 (1H, bd), 4.18 (1H, m), 4.35 (1H, m), 4.85 (1H, m),  
35 5.17 (1H, m), 5.54 (1H, dd), 5.68 (1H, d), 5.91 (1H, dd), 5.99 (1H, d,  $\underline{J}$  11.3). 6.15 (1H, dd), 6.22 (1H, d,  $\underline{J}$  11.3).

Preparation 21 Compound 114j

The compound was prepared by following the procedure described in Preparation 19 and by using ethyl-lithium instead of methyl-lithium. (Eluant: hexane-ether 80:20)  
5 114j;  $\delta$  (300 MHz) 0.05 (12H, m), 0.50 (3H, s), 0.85 (6H, t), 0.85 (9H, s), 0.89 (9H, s), 0.94 (3H, d,  $\underline{J}$  6.6), 1.05-2.15 (19H, m), 2.30 (1H, bd), 2.55 (1H, dd), 2.85 (1H, bd), 4.21 (1H, m), 4.52 (1H, m), 4.93 (1H, m), 4.97 (1H, m), 5.50 (1H, d), 5.53 (1H, dd), 5.80 (1H, d,  $\underline{J}$  11.5), 5.94  
10 (1H, dd), 6.15 (1H, dd), 6.44 (1H, d,  $\underline{J}$  11.5).

Preparation 22 Compound 114k

The compound was prepared using Procedure 6 in which starting material II was compound 114j. (Eluant:  
15 hexane-ether 90:10) 114k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.48 3H, s), 0.86 (6H, t), 0.87 (9H, s), 0.88 (9H, s), 0.94 (3H, d,  $\underline{J}$  6.6), 1.00-2.15 (19H, m), 2.20 (1H, dd), 2.43 (1H, dd), 2.79 (1H, bd), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17 (1H, m), 5.50 (1H, d), 5.53 (1H, dd), 5.93 (1H,  
20 dd), 6.00 (1H, d), 6.14 (1H, dd), 6.22 (1H, d).

Preparation 23 Compound 117j

The compound was prepared using Procedure 1 in which the starting material was compound 2bj (x=2). (Eluant:  
25 hexane-ether 70:30) 117j;  $\delta$  (300 MHz) 0.05 (12H, m), 0.49 (3H, s), 0.85 (9H, s), 0.89 (9H, s), 0.94 (3H, d,  $\underline{J}$  6.6), 1.05-2.17 (15H, m), 2.30 (1H, bd), 2.55 (1H, dd), 2.84 (1H, bd), 4.16 (2H, m), 4.21 (1H, m), 4.52 (1H, m), 4.93 (1H, m), 4.97 (1H, m), 5.58 (1H, dd), 5.71 (1H, m), 5.81 (1H, d,  
30  $\underline{J}$  11.4), 5.96 (1H, dd), 6.20 (1H, dd), 6.44 (1H, d,  $\underline{J}$  11.4).

Preparation 24 Compound 117k

The compound was prepared using Procedure 6 in which  
35 starting material II was compound 117j. (Eluant: hexane-ether 70:30) 117k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.48 (3H, s), 0.86 (9H, s), 0.87 (9H, s), 0.93 (3H, d), 1.02-2.15 (15H, m), 2.21 (1H, dd), 2.43 (1H, dd), 2.80 (1H, bd), 4.16 (2H,

bd), 4.19 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17 (1H, m), 5.57 (1H, dd), 5.70 (1H, m), 5.95 (1H, dd), 6.00 (1H, d), 6.20 (2H, m).

5        Preparation 25    Compound 119j

The compound was prepared using Procedure 4 in which the alkyl-lithium was n-propyl-lithium and the starting material was 2aj (x=2). 119j;  $\delta$  (300 MHz) 0.05 (12H, m), 0.55 (3H, s), 0.86 (9H, s), 0.89 (9H, s), 0.89 (6H, t),  
10 1.05 (3H, d,  $J$  6.6), 1.15-2.20 (23H, m), 2.30 (1H, bd), 2.55 (1H, dd), 2.87 (1H, bd), 4.21 (1H, m), 4.52 (1H, m), 4.93 (1H, m), 4.98 (1H, m), 5.50 (1H, dd), 5.54 (1H, d), 5.81 (1H, d,  $J$  11.4), 5.95 (1H, dd), 6.13 (1H, dd), 6.45 (1H, d,  $J$  11.4).

15

Preparation 26    Compound 119k

The compound was prepared using Procedure 6 in which starting material II was compound 119j. (Eluant: hexane-ether 85:15) 119k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.54 (3H, s), 0.86 (18H, s), 0.89 (6H, t), 1.04 (3H, d,  $J$  6.6),  
20 1.15-2.15 (23H, m), 2.20 (1H, dd), 2.43 (1H, dd), 2.81 (1H, bd), 4.18 (1H, m), 4.35 (1H, m), 4.85 (1H, m), 5.16 (1H, m), 5.52 (1H, dd), 5.53 (1H, dd), 5.94 (1H, dd), 6.00 (1H, d), 6.12 (1H, dd), 6.22 (1H, d).

25

Preparation 27    Compound 121k

Compound 121j was prepared by using Procedure 1 in which the starting material was compound 2aj (x=2). The crude 121j was of sufficient purity for use as starting  
30 material in Procedure 6 by which method it was transformed into compound 121k. (Eluant: hexane-ether 70:30). 121k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.54 (3H, s), 0.86 (18H, s), 1.04 (3H, d,  $J$  6.6), 1.12-2.30 (16H, m), 2.44 (1H, dd), 2.82 (1H, bd), 4.15 (2H, m), 4.17 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.16 (1H, m), 5.57 (1H, dd), 5.70 (1H, m), 5.97 (1H, dd), 6.00 (1H, d), 6.18 (1H, dd), 6.22 (1H, d).

35

Preparation 28 Compound 2ak (x=1)

Using the method of Preparation 2 and by starting from 1ak instead of 1aj compound 2ak (x=1) was obtained as an oil.  $\delta$  (300 MHz) 0.05 (12H, bs), 0.55 (3H, s), 0.87 (18H, s), 1.08 (3H, d), 1.15-2.10 (12H, m), 2.10-2.35 (3H, m), 2.44 (1H, dd), 2.82 (1H, bd), 3.70 (3H, s), 4.18 (1H, m), 4.36 (1H, m), 4.83 (1H, bd), 5.16 (1H, bd), 5.74 (1H, d), 6.00 (1H, d), 6.22 (1H, d), 6.87 (1H, dd).

Preparation 29 Compound 123k

The compound was prepared using Procedure 1 in which the starting material was compound 2ak (x=1). (Eluant: hexane-ether 7:3). 123k;  $\delta$  (300 MHz) 0.05 (12H, m), 0.54 (3H, s), 0.87 (18H, s), 1.03 (3H, d, J 6.6), 1.12-2.30 (16H, m), 2.44 (1H, dd), 2.82 (1H, bd), 4.06 (2H, m), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17 (1H, m), 5.54 (2H, m), 6.00 (1H, d, J 11.2), 6.22 (1H, d, J 11.2).

Preparation 30 Compound 3ak (x=1)

Using the method of Preparation 5 (compound 123k as starting material), compound 3ak (x=1) was prepared and purified by chromatography (Eluant: hexane-ether 4:1).  $\delta$  (300 MHz) 0.05 (12H, m), 0.57 (3H, s), 0.86 (18H, s), 1.14 (3H, d, J 6.6), 1.10-1.90 (12H, m), 1.98 (1H, bd), 2.21 (1H, dd), 2.43 (2H, m), 2.83 (1H, bd), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17 (1H, m), 6.04 (2H, m), 6.22 (1H, d, J 11.3), 6.70 (1H, dd), 9.47 (1H, d, J 7.8).

Preparation 31 Compound 2ak (x=3)

This compound was prepared by using the method of Preparation 6 and by starting from 3ak (x=1) instead of 1aj. The reaction mixture was only kept at 62°C for 2 hours. Compound 2ak (x=3) was isolated by chromatography. (Eluant: hexane-ether 4:1).  $\delta$  (300 MHz) 0.05 (12H, m), 0.55 (3H, s), 0.87 (18H, s), 1.06 (3H, d, J 6.6), 1.15-2.30 (15H, m), 2.43 (1H, dd), 2.82 (1H, bd), 3.73 (3H, s), 4.18 (1H, m), 4.35 (1H, m), 4.84 (1H, m), 5.16 (1H, m), 5.79 (1H, dd), 5.82 (1H, d), 5.95-6.25 (4H, m), 6.50 (1H, dd),

7.29 (1H, dd).

Preparation 32 Compound 124k

The compound was prepared by following Procedure 4  
5 and by using methyl-lithium and 2ak (x=3) as starting  
material. (Eluant: hexane-ether 4:1).  $\delta$  (300 MHz) 0.05  
(12H, m), 0.54 (3H, s), 0.86 (18H, s), 1.04 (3H, d,  $J$  6.6),  
1.33 (6H, s), 1.15-2.30 (16H, m), 2.44 (1H, dd), 2.82 (1H,  
bd), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.16 (1H,  
10 m), 5.56 (1H, dd), 5.78 (1H, d), 5.92-6.30 (6H, m).

Preparation 33 Compound 126k

The compound was prepared by following Procedure 4  
and by using ethyl-lithium and 2ak (x=3) as starting  
15 material. (Eluant: hexane-ether 4:1).  $\delta$  (300 MHz) 0.05  
(12H, m), 0.54 (3H, s), 0.84 (6H, t), 0.87 (18H, s), 1.04  
(3H, d,  $J$  6.5), 1.00-2.30 (20H, m), 2.44 (1H, dd), 2.81  
(1H, bd), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17  
(1H, m), 5.56 (1H, dd), 5.59 (1H, d), 6.00 (2H, m), 6.16  
20 (4H, m).

Preparation 34 Compound 128k

This compound was prepared using Procedure 1 in which  
the starting material was compound 2ak (x=3).  $\delta$  (300 MHz)  
25 0.05 (12H, m), 0.54 (3H, s), 0.87 (18H, s), 1.04 (3H, d,  $J$   
6.6), 1.12-2.25 (16H, m), 2.43 (1H, dd), 2.82 (1H, bd),  
4.18 (3H, m), 4.36 (1H, m), 4.85 (1H, m), 5.16 (1H, m),  
5.59 (1H, dd), 5.79 (1H, m), 5.90-6.30 (6H, m).

30 Preparation 35 Compound 107k

This compound was prepared using Procedure 6 in which  
starting material II was compound 107j.  $\delta$  (300 MHz) 0.05  
(12H, m), 0.54 (3H, s), 0.87 (18H, s), 1.04 (3H, d),  
1.15-2.15 (22H, m), 2.21 (2H, d), 2.40 (1H, m), 2.82 (1H,  
35 bd), 4.18 (1H, m), 4.36 (1H, m), 4.85 (1H, m), 5.17 (1H,  
m), 5.51 (1H, dd), 5.60 (1H, m), 6.00 (3H, m), 6.24 (1H,  
d).

Procedure 7Preparation of Compound I from the  
Corresponding Compound II or V (R=k)  
(Scheme 4)

A solution of the compound II or V (0.2 g) and tetra-  
5 n-butylammonium fluoride trihydrate (0.4 g) in THF (10 ml)  
was heated at 60°C under an atmosphere of nitrogen for 50  
minutes. After cooling, the reaction solution was parti-  
tioned between ethyl acetate (40 ml) and 2% sodium hydrogen  
carbonate solution (30 ml), and the organic layer was  
10 washed with water and brine, dried and concentrated. The  
residue was purified by chromatography (30 g silica gel,  
ethyl acetate as eluant) to give I.

The compounds of Examples 1-4 and 6-14 were prepared  
15 using procedure 7. The respective starting materials II or  
V are given in the Examples.

Example 1

20 20(R)-(5'-Cyclopropyl-5'-hydroxy-  
penta-1'(E),3'(E)-dien-1'-yl)-1(S),  
3(R)-dihydroxy-9,10-secopregna-5(Z),  
7(E),10(19)-triene (Isomer A)  
(Compound 108)

Starting material 102k;  $\delta$  (300 MHz) 0.20-0.40 (2H,  
m), 0.53 (3H, s), 0.46-0.65 (2H, m), 1.05 (3H, d,  $\underline{J}$  6.6),  
25 0.90-2.20 (18H, m), 2.31 (1H, dd), 2.60 (1H, m), 2.83 (1H,  
m), 3.49 (1H, t), 4.23 (1H, m), 4.43 (1H, m), 5.00 (1H, m),  
5.33 (1H, m), 5.57 (1H, dd,  $\underline{J}$  15 and 8.7), 5.66 (1H, dd,  $\underline{J}$   
15 and 6.5), 5.97 (1H, dd,  $\underline{J}$  15 and 10.3), 6.01 (1H, d,  $\underline{J}$   
11.2) 6.17 (1H, dd,  $\underline{J}$  15 and 10.3), 6.38 (1H, d,  $\underline{J}$  11.2).

30

Example 2

35 20(R)-(5'-Cyclopropyl-5'-hydroxy-  
penta-1'(E),3'(E)-dien-1'-yl)-1(S),  
3(R)-dihydroxy-9,10-secopregna-5(Z),  
7(E),10(19)-triene (Isomer B)  
(Compound 109)

35

Starting material: 103k;  $\delta$  (300 MHz) 0.22-0.40 (2H,  
m), 0.56 (3H, s), 0.46-0.65 (2H, m), 1.05 (3H, d,  $\underline{J}$  6.6),  
0.90-2.20 (18H, m), 2.31 (1H, dd), 2.60 (1H, m), 2.84 (1H,

m), 3.50 (1H, t), 4.23 (1H, m), 4.43 (1H, m), 5.00 (1H, m), 5.33 (1H, m), 5.58 (1H, dd,  $J$  15.1 and 8.6), 5.67 (1H, dd,  $J$  15.2 and 6.3), 5.97 (1H, dd,  $J$  15.1 and 10.3), 6.01 (1H, d,  $J$  11.3) 6.19 (1H, dd,  $J$  15.1 and 10.3), 6.38 (1H, d,  $J$  11.3).

Example 3

1(S),3(R)-Dihydroxy-20(R)-(5'-hydroxy-5'-methyl-hexa-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E)-10(19)-triene (Compound 110)

10

Starting material: 104k. Crystallisation from ethyl acetate-hexane gave needles, m.p. 156-157°C;  $\lambda_{\max}$  231 nm ( $\epsilon$  = 42530) and 264 nm ( $\epsilon$  = 18040);  $\delta$  (300 MHz) 0.56 (3H, s), 1.05 (3H, d,  $J$  6.6), 1.34 (6H, s), 1.15-2.20 (17H, m), 2.31 (1H, dd), 2.60 (1H, dd), 2.84 (1H, m), 4.23 (1H, m), 4.43 (1H, m), 5.00 (1H, m), 5.33 (1H, m), 5.56 (1H, dd), 5.71 (1H, dd,  $J$  15.4), 5.96 (2H, m), 6.16 (1H, dd), 6.38 (1H, d,  $J$  11.2).

20

Example 4

1(S),3(R)-Dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene (Compound 111)

Starting material: 105k. Crystallisation from methyl format-hexane gave needles, m.p. 123-125°C;  $\lambda_{\max}$  232 nm ( $\epsilon$  = 43745) and 264 nm ( $\epsilon$  = 18060);  $\delta$  (300 MHz) 0.55 (3H, s), 0.85 (6H, t), 1.04 (3H, d,  $J$  6.6), 1.12-2.20 (21H, m), 2.30 (1H, dd), 2.58 (1H, dd), 2.82 (1H, dd), 4.21 (1H, m), 4.41 (1H, m), 4.99 (1H, m), 5.31 (1H, m), 5.53 (2H, m), 5.95 (1H, dd,  $J$  15 and 10.3), 6.00 (1H, d,  $J$  11.3), 6.14 (1H, dd,  $J$  15 and 10.3), 6.37 (1H, d,  $J$  11.3).

30

Example 5

1(S),3(R)-Dihydroxy-20(R)-(6'-hydroxy-hexa-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene (Compound 112)

35

A solution of MC 903 [M.J. Calverley, Tetrahedron 43, 4609 (1987)] (0.45 g) in a mixture of alcohol-free

chloroform (20 ml) and trifluoroacetic anhydride (9 ml) was kept at room temperature for 50 minutes. The reaction mixture was then slowly added to an ice-cold stirred solution of potassium hydroxide (19.8 g) in methanol (150 ml). After stirring for 10 minutes and concentration in vacuo, the residue was partitioned between methylene chloride and water. The organic layer was dried and concentrated. Purification by chromatography (silica gel, hexane-ethyl acetate 1:3 as eluant) gave the title compound which crystallized from ethyl acetate, m.p.: 132-35°C;  $\lambda_{\text{max}}$  = 232 nm ( $\epsilon$  = 40980) and 264 nm ( $\epsilon$  = 17494);  $\delta$  (300 MHz) 0.56 (3H, s), 1.04 (3H, d,  $J$  6.6), 1.15-2.25 (17H, m), 2.32 (3H, m), 2.60 (1H, dd), 2.82 (1H, dd), 3.66 (2H, m), 4.22 (1H, m), 4.43 (1H, m), 4.99 (1H, s), 5.32 (1H, s), 5.50 (2H, m), 6.00 (3H, m), 6.37 (1H, d,  $J$  11.2).

Example 6

1(S),3(R)-Dihydroxy-20(R)-(6'-hydroxy-6'-methyl-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E)-10(19)-triene (Compound 133)

20

Starting material: 107k; Crystallization from methyl formate-hexane, m.p. 147-148°C;  $\lambda_{\text{max}}$  233 nm ( $\epsilon$  = 43322) and 264 nm ( $\epsilon$  = 17916);  $\delta$  (300 MHz) 0.56 (3H, s), 1.05 (3H, d), 1.22 (6H, s), 1.20-2.20 (17H, m), 2.23 (2H, d), 2.31 (1H, dd), 2.60 (1H, dd), 2.83 (1H, bd), 4.23 (1H, m), 4.43 (1H, m), 5.00 (1H, m), 5.32 (1H, m), 5.50 (1H, dd), 5.60 (1H, m), 6.01 (3H, m), 6.38 (1H, d).

25

Example 7

1(S),3(R)-Dihydroxy-20(R)-(7'-hydroxy-hepta-1'(E),3'(E),5'(E)-trien-1'-yl)-9,10-secopregna-5(Z),7(E),-10(19)-triene (Compound 129)

30

Starting material: 128k;  $\delta$  (300 MHz) 0.59 (3H, s), 1.06 (3H, d,  $J$  6.6), 1.89 (2H, t), 1.15-2.21 (15H, m), 2.25 (1H, dd), 2.52 (1H, dd), 2.87 (1H, bd), 4.09 (2H, bd), 4.12 (1H, m), 4.35 (1H, m), 4.89 (1H, m), 5.28 (1H, m), 5.56 (1H, dd), 5.75 (1H, m), 5.95-6.36 (6H, m).

35



Example 8                    1(S),3(R)-Dihydroxy-20(S)-(5'-  
-hydroxy-5'-methyl-hexa-1'(E),3'(E)-  
-dien-1'-yl)-9,10-secopregna-5(Z),  
7(E),10(19)-triene (Compound 115)

5            Starting material: 113k. The compound crystallized  
from ethyl acetate-hexane, m.p. 98-102°C;  $\lambda_{\text{max}}$  232 nm ( $\epsilon$  =  
38238) and 265 nm ( $\epsilon$  = 17418);  $\delta$  (300 MHz) 0.50 (3H, s),  
0.94 (3H, d,  $J$  6.6), 1.35 (6H, s), 1.05-2.15 (17H, m), 2.31  
(1H, dd), 2.57 (1H, bd), 2.82 (1H, bd), 4.22 (1H, m), 4.43  
10 (1H, m), 5.00 (1H, m), 5.33 (1H, m), 5.56 (1H, dd), 5.69  
(1H, d), 5.92 (1H, dd), 6.01 (1H, d,  $J$  11.3), 6.16 (1H,  
dd), 6.37 (1H, d,  $J$  11.3).

Example 9                    1(S),3(R)-Dihydroxy-20(S)-(5'-ethyl-  
15 -5'-hydroxy-hepta-1'(E),3'(E)-dien-  
-1'-yl)-9,10-secopregna-5(Z),7(E),  
10(19)-triene (Compound 116)

Starting material: 114k;  $\lambda_{\text{max}}$  233 and 264 nm;  $\delta$  (300  
MHz) 0.51 (3H, s), 0.87 (6H, t), 0.95 (3H, d,  $J$  6.7),  
20 1.02-2.15 (21H, m), 2.31 (1H, dd), 2.60 (1H, bd), 2.81 (1H,  
bd), 4.23 (1H, m), 4.43 (1H, m), 5.00 (1H, m), 5.33 (1H,  
m), 5.51 (1H, d), 5.53 (1H, dd), 5.95 (1H, dd), 6.01 (1H,  
d), 6.16 (1H, dd), 6.38 (1H, d,  $J$  11.2).

Example 10                    1(S),3(R)-Dihydroxy-20(S)-(5'-  
25 -hydroxy-penta-1'(E),3'(E)-dien-1'-  
-yl-9,10-secopregna-5(Z),7(E),  
10(19)-triene (Compound 118)

Starting material: 117k;  $\delta$  (300 MHz) 0.50 (3H, s),  
30 0.94 (3H, d,  $J$  6.6), 1.02-2.20 (17H, m), 2.31 (1H, dd),  
2.59 (1H, dd), 2.81 (1H, bd), 4.17 (2H, bd), 4.23 (1H, m),  
4.42 (1H, m), 5.00 (1H, m), 5.33 (1H, m), 5.58 (1H, dd),  
5.72 (1H, m), 5.96 (1H, dd), 6.01 (1H, d,  $J$  11.3), 6.21  
(1H, dd), 6.37 (1H, d,  $J$  11.3).

Example 11      1(S),3(R)-Dihydroxy-20(R)-(5'-hydr-  
-oxy-5'-n-propyl-octa-1'(E),3'(E)-  
-dien-1'-yl)-9,10-secopregna-5(Z),  
7(E),10(19)-triene (Compound 120)

5      Starting material: 119k;  $\delta$  (300 MHz) 0.55 (3H, s),  
0.89 (6H, t), 1.04 (3H, d,  $J$  6.6), 1.15-2.18 (25H, m), 2.30  
(1H, dd), 2.59 (1H, dd), 2.82 (1H, bd), 4.21 (1H, m), 4.41  
(1H, m), 4.98 (1H, m), 5.31 (1H, m), 5.52 (1H, dd), 5.54  
(1H, d), 5.93 (1H, dd), 6.00 (1H, d), 6.12 (1H, dd), 6.36  
10 (1H, d,  $J$  11.2).

Example 12      1(S),3(R)-Dihydroxy-20(R)-(5'-  
-hydroxy-penta-1'(E),3'(E)-dien-1'-  
-yl-9,10-secopregna-5(Z),7(E),  
15 10(19)-triene (Compound 122)

Starting material: 121k. Crystals from methyl  
formate; m.p.: 154-155°C;  $\lambda_{\max}$  231 nm ( $\epsilon$  = 41228) and 264  
nm ( $\epsilon$  = 17876);  $\delta$  (300 MHz) 0.58 (3H, s), 1.05 (3H, d,  $J$   
6.6), 1.15-1.80 (12H, m), 1.89 (2H, t), 2.01 (2H, m), 2.14  
20 (1H, m), 2.26 (1H, dd), 2.52 (1H, dd), 2.87 (1H, bd), 4.06  
(2H, m), 4.12 (1H, m), 4.35 (1H, t), 4.89 (1H, m), 5.28  
(1H, m), 5.53 (1H, dd), 5.67 (1H, d), 5.98 (1H, dd), 6.08  
(1H, d,  $J$  11.2), 6.16 (1H, dd), 6.32 (1H, d,  $J$  11.2).

25 Example 13      1(S),3(R)-Dihydroxy-20(R)-(7'-hydr-  
-oxy-7'-methyl-octa-1'(E),3'(E)-  
5'(E)-trien-1'-yl)-9,10-secopregna-  
-5(Z),7(E),10(19)-triene (Compound  
125

30      Starting material: 124k. Compound 125 was  
crystallized from methyl formate;  $\lambda_{\max}$  259 nm ( $\epsilon$  = 53692),  
268 nm ( $\epsilon$  = 67103), and 279 nm ( $\epsilon$  = 53256);  $\delta$  (300 MHz)  
0.56 (3H, s), 1.05 (3H, d,  $J$  6.6), 1.34 (6H, s), 1.15-2.20  
(17H, m), 2.31 (1H, dd), 2.60 (1H, bd), 2.83 (1H, bd), 4.22  
35 (1H, m), 4.42 (1H, m), 4.99 (1H, m), 5.32 (1H, m), 5.57  
(1H, dd), 5.79 (1H, d), 5.90-6.30 (5H, m), 6.38 (1H, d,  $J$   
11.2).

Example 14      1(S),3(R)-Dihydroxy-20(R)-(7'-hydr-  
-oxy-7'-ethyl-nona-1'(E),3'(E)-  
5'(E)-trien-1'-yl)-9,10-secopregna-  
-5(Z),7(E),10(19)-triene (Compound  
127

5  
 Starting material 126k. Crystals from methyl  
 formate-hexane; m.p.: 115-118°C.  $\lambda_{\max}$  260 nm ( $\epsilon$  = 58040),  
 270 nm ( $\epsilon$  = 72111), and 281 nm ( $\epsilon$  = 56714);  $\delta$  (300 MHz)  
 0.56 (3H, s), 0.85 (6H, t), 1.05 (3H, d,  $J$  6.6), 1.15-2.20  
 10 (21H, m), 2.31 (1H, dd), 2.60 (1H, dd), 2.83 (1H, bd), 4.22  
 (1H, m), 4.42 (1H, m), 5.00 (1H, m), 5.32 (1H, m), 5.59  
 (1H, dd), 5.61 (1H, d), 6.00 (2H, m), 6.10-6.30 (3H, m),  
 6.37 (1H, d,  $J$  11.3).

15      Example 15      20(S)-(5'-Cyclopropyl-5'-hydroxy-  
-penta-1'(E),3'(E)-dien-1'-yl)-1(S),  
3(R)-dihydroxy-9,10-secopregna-5(Z),  
7(E),10(19)-triene (Compounds 131 and  
132)

20      These two isomeric compounds are prepared by using  
 the procedures described in Preparations 8, 9, 14, 15 and  
 Examples 1 and 2 and by substituting 3bj ( $x=1$ ) (described  
 in British patent application No. 8914963.7) for 3aj ( $x=1$ )  
 in Preparation 8.

25      Example 16      1(S),3(R)-Dihydroxy-20(S)-(6'-hydr-  
-oxy-hexa-1'(E),3'(E)-dien-1'-yl)-  
-9,10-secopregna-5(Z),7(E),10(19)-  
-triene (Compound 130)

30      This compound was prepared by following the procedure  
 described in Example 5 and by using 20(S)-(3'-cyclopropyl-  
 -3'-hydroxyprop-1'(E)-enyl)-1(S),3(R)-dihydroxy-9,10-seco-  
 pregna-5(Z),7(E),10(19)-triene - isomer A or isomer B or  
 mixtures thereof - (described in British patent application  
 35 No. 8914963.7) as starting material instead of MC 903.

$\delta$  (300 MHz) 0.50 (3H, s), 0.93 (3H, d), 1.05-2.10  
 (17H, m), 2.30 (1H, m), 2.34 (2H, q), 2.58 (1H, dd), 2.81  
 (1H, bd), 3.67 (2H, t), 4.22 (1H, m), 4.42 (1H, m), 4.99

(1H, bs), 5.32 (1H, bs), 5.45-5.60 (2H, m), 5.85-6.15 (3H, m), 6.37 (1H, d).

5            Example 17            1(S),3(R)-Dihydroxy-20(S)-(6'-hydr-  
                                 -oxy-6'-methyl-hepta-1'(E),3'(E)-  
                                 -dien-1'-yl)-9,10-secopregna-5(Z),  
                                 7(E),10(19)-triene (Compound 134)

                 This compound is prepared by using the procedure  
described in Preparations 13 and 35 and Procedure 7 and by  
10 substituting 3bj (x=1) (described in British patent  
application No. 8914963.7) for 3aj (x=1) in Preparation  
13.

15            Example 18            1(S),3(R)-Dihydroxy-20(S)-(6'-ethyl-  
                                 -6'-hydroxy-octa-1'(E),3'(E)-  
                                 -dien-1'-yl)-9,10-secopregna-5(Z),  
                                 7(E),10(19)-triene (Compound 135)

                 This compound is prepared by using the procedure  
described in Example 17 but substituting compound 12 for  
20 compound 11 in Preparation 13.

Example 19            1(S),3(R)-Dihydroxy-20(R)-(6'-ethyl-  
                                 -6'-hydroxy-octa-1'(E),3'(E)-  
                                 -dien-1'-yl)-9,10-secopregna-5(Z),  
25                                7(E),10(19)-triene (Compound 136)

                 This compound is prepared by using the procedure  
described in Preparations 13 and 35 and Procedure 7 but  
substituting compound 12 for compound 11 in Preparation  
13;  $\delta$  (300 MHz) 0.56 (3H, s), 0.88 (6H, t), 1.04 (3H, d),  
30 1.48 (4H, q), 1.15-2.17 (17H, m), 2.20 (2H, d), 2.32 (1H,  
dd), 2.60 (1H, dd), 2.83 (1H, dd), 4.23 (1H, m), 4.43 (1H,  
m), 5.00 (1H, m), 5.32 (1H, m), 5.52 (2H, m), 6.00 (3H,  
m), 6.38 (1H, d).

Example 20

1(S),3(R)-Dihydroxy-20-(5',6'-di-  
-methyl-6'-hydroxy-hepta-1'(E),3'(E)-  
-dien-1'-yl)-9,10-secopregna-5(Z),  
7(E),10(19)-triene  
(Compounds 137-140)

5

The four diastereoisomers of the title compound are prepared separately using the methods of Procedures 5, 6 and 7 and the appropriate starting materials 3aj (x=1) or 3bj (x=1) and 17 or 18.

10

Example 21Dermatological Cream Containing  
Compound 111

In 1 g almond oil was dissolved 0.1 mg 111. To this solution was added 40 g of mineral oil and 20 g of  
15 self-emulsifying beeswax. The mixture was heated to liquify. After the addition of 40 ml hot water, the mixture was mixed well. The resulting cream contains approximately 1 µg of 111 per gram of cream.

20

Example 22Capsules containing Compound 111


111 was suspended in arachis oil to a final concentration of 5 µg 111/ml oil. 10 Parts by weight of gelatine, 5 parts by weight glycerine, 0.08 parts by weight potassium sorbate, and 14 parts by weight distilled water  
25 were mixed together with heating and formed into soft gelatine capsules. These were then filled each with 100 µl of the 111 in oil suspension, such that each capsule contained 0.5 µg 111.

30

35

## WHAT WE CLAIM IS:

1. A compound of the formula I



in which formula,  $n$  is 2 or 3,  $m$  is 0 or an integer from 1 - 4;  $R^1$  and  $R^2$  (which may be the same or different) stand for hydrogen or  $C_1$ - $C_8$ -hydrocarbyl, hydrocarbyl indicating the residue after removal of a hydrogen atom from a straight, branched or cyclic saturated or unsaturated hydrocarbon, or taken together with the carbon bearing the hydroxyl group (starred in formula I),  $R^1$  and  $R^2$  can form a saturated or unsaturated  $C_3$ - $C_8$  carbocyclic ring; in addition,  $R^1$  and/or  $R^2$  and/or one of the  $m$  carbons designated by the "°" may be optionally substituted with one or more chlorine or fluorine atom(s); and finally one of the carbons designated "°" may optionally be substituted by one or two  $C_1$ - $C_2$  alkyl group(s); and derivatives of the compounds of formula I in which one or more hydroxy have been transformed into -O-acyl or -O-glycosyl or phosphate ester groups; such masked groups being hydrolyzable in vivo; and other prodrugs thereof.

**SUBSTITUTE SHEET**

2. A diastereoisomer of a compound according to claim 1, in pure form; or a mixture of diastereoisomers of a compound according to claim 1.

5 3. A compound according to claim 1 selected from the groups consisting of the 20(R) and 20(S) isomers of:

10 1(S),3(R)-Dihydroxy-20-(5'-hydroxy-5'-methyl-hexa-  
-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),-  
10(19)-triene;

15 1(S),3(R)-Dihydroxy-20-(5'-ethyl-5'-hydroxy-hepta-  
-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),-  
10(19)-triene;

1(S),3(R)-Dihydroxy-20-(6'-hydroxy-hexa-1'(E),-  
3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),-  
10(19)-triene;

20 1(S),3(R)-Dihydroxy-20-(5'-cyclopropyl-5'-hydroxy-  
-penta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),-  
7(E),10(19)-triene (5'(R) and 5'(S) isomers);

25 1(S),3(R)-Dihydroxy-20-(6'-hydroxy-6'-methyl-hepta-  
-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),-  
10(19)-triene;

4. A method for producing a compound of formula I of claim 1 or an analogue thereof by which:

30 a) the side chain attached to C-20 in compound I is elaborated from the 20(R) or 20(S) isomers of 1(S),3(R)-  
-bis-(tert-butyldimethylsilyloxy)-20-formyl-9,10-seco-  
pregna-5(E),7(E),10(19)-triene or 1(S),3(R)-bis-(tert-  
35 butyldimethylsilyloxy)-20-(2'-formyl-1'(E)-ethen-1'-yl)-  
9,10-secopregna-5(E),7(E),10(19)-triene or their  
corresponding 5(Z)isomers, either

- (i) by reaction with a Wittig-type reagent (e.g.  $\text{Ph}_3\text{P}^+-\text{CH}^--\text{CH}=\text{CH}-\text{COOCH}_3$ ) followed by reaction of the resulting ester with an organometallic reagent (e.g.  $\text{R}^1\text{Li}$ ) or a reducing agent (e.g.  $i\text{-Bu}_2\text{AlH}$ ), or
- (ii) by reaction with a Wittig-type reagent (e.g.  $\text{Ph}_3\text{P}^+-\text{CH}^--\text{C}(\text{O})-\text{R}^2$ ) followed by reaction of the resulting ketone with a reducing agent (e.g.  $\text{NaBH}_4$ ), or
- (iii) by reaction with the carbanion derived from the sulfone  $\text{PhS}(\text{O}_2)\text{CH}_2-(^\circ\text{CH}_2)_m-\text{C}(\text{OH})\text{R}^1\text{R}^2$  by treatment with base (e.g. two equivalents of lithium di-isopropylamide) followed by reductive elimination of the product  $\beta$ -hydroxy-sulphone (e.g. with sodium amalgam) (optionally after derivatisation of the  $\beta$ -hydroxy group e.g. with benzoyl chloride and base), and
- b) the compound from step (a) above is optionally (i) separated from diastereoisomers (e.g. by chromatography), (ii) subjected to a triplet-sensitized photoisomerisation to the 5Z isomer, and (iii) desilylated e.g. with tetrabutylammonium fluoride, the order of these options being arbitrary.
5. A method for producing the 20(R) and 20(S) isomers of 1(S),3(R)-dihydroxy-20-(6'-hydroxy-hexa-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E)-10(19)-triene by treating the 20(R) and 20(S) isomers of 1(S),3(R)-dihydroxy-20-(3'cyclopropyl-3'-hydroxyprop-1'(E)-en-1'-yl)-9,10-secopregna-5(Z),7(E)-10(19)-triene with a carboxylic anhydride (e.g. trifluoroacetic anhydride) and subjecting the product to basic hydrolysis (e.g. with alcoholic alkali hydroxide).
6. A pharmaceutical composition containing an effective amount of one or more of the compounds of claim 1, together



with pharmaceutically acceptable, non-toxic carriers and/or auxiliary agents.

7. A pharmaceutical composition according to claim 6 for  
5 topical use containing from 0.1 - 100 µg/g of a compound of formula I.

8. A pharmaceutical composition according to claim 6 in  
10 dosage unit form.

9. A dosage unit according to claim 8 containing from  
0.01 - 100 µg for oral and parenteral formulations of a  
compound of formula I.

15 10. A method for the treatment or prophylaxis of auto-immune diseases (including diabetes mellitus), hypertension, acne, alopecia, skin ageing (including photo-ageing), inflammatory diseases such as rheumatoid  
20 arthritis and asthma, as well as diseases characterized by abnormal cell differentiation and/or cell proliferation, and/or imbalance in the immune system.

11. A method according to claim 10 for the treatment or  
25 prophylaxis of cancer.

12. A method according to claim 10 for the treatment or  
prophylaxis of psoriasis.

13. A method according to claim 10 for the treatment or  
30 prophylaxis of skin ageing.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 90/00168

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 C 401/00, A 61 K 31/59														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched<sup>7</sup></div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%;">Classification System</th> <th style="width: 75%;">Classification Symbols</th> </tr> <tr> <td style="height: 40px; vertical-align: bottom;">IPC5</td> <td style="vertical-align: bottom;">C 07 C; A 61 K</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched<sup>8</sup></div> <p style="margin-top: 10px;">SE,DK,FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	C 07 C; A 61 K								
Classification System	Classification Symbols													
IPC5	C 07 C; A 61 K													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 60%;">Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 30%;">Relevant to Claim No.<sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td style="vertical-align: top;">US, A, 4505906 (HECTOR F. DELUCA ET AL.) 19 March 1985, see especially column 2 --</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">WO, A1, 8503939 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 12 September 1985, see the whole document --</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td style="vertical-align: top;">Biochemical Pharmacology, Vol. 37, No. 5, 1988 Lise Binderup et al.: "Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo ", see page 889 - page 895 -- -----</td> <td style="text-align: center; vertical-align: top;">1-9</td> </tr> </tbody> </table>			Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	US, A, 4505906 (HECTOR F. DELUCA ET AL.) 19 March 1985, see especially column 2 --	1-9	A	WO, A1, 8503939 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 12 September 1985, see the whole document --	1-9	A	Biochemical Pharmacology, Vol. 37, No. 5, 1988 Lise Binderup et al.: "Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo ", see page 889 - page 895 -- -----	1-9
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X	US, A, 4505906 (HECTOR F. DELUCA ET AL.) 19 March 1985, see especially column 2 --	1-9												
A	WO, A1, 8503939 (WISCONSIN ALUMNI RESEARCH FOUNDATION) 12 September 1985, see the whole document --	1-9												
A	Biochemical Pharmacology, Vol. 37, No. 5, 1988 Lise Binderup et al.: "Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo ", see page 889 - page 895 -- -----	1-9												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><b>* Special categories of cited documents:</b> <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 50%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;">           Date of the Actual Completion of the International Search   <b>10th October 1990</b> </td> <td style="width: 50%; padding: 5px;">           Date of Mailing of this International Search Report   <b>1990 -10- 1 2</b> </td> </tr> <tr> <td style="width: 50%; padding: 5px;">           International Searching Authority   <b>SWEDISH PATENT OFFICE</b> </td> <td style="width: 50%; padding: 5px;">           Signature of Authorized Officer   <b>Anna Hedberg</b> </td> </tr> </table>			Date of the Actual Completion of the International Search  <b>10th October 1990</b>	Date of Mailing of this International Search Report  <b>1990 -10- 1 2</b>	International Searching Authority  <b>SWEDISH PATENT OFFICE</b>	Signature of Authorized Officer  <b>Anna Hedberg</b>								
Date of the Actual Completion of the International Search  <b>10th October 1990</b>	Date of Mailing of this International Search Report  <b>1990 -10- 1 2</b>													
International Searching Authority  <b>SWEDISH PATENT OFFICE</b>	Signature of Authorized Officer  <b>Anna Hedberg</b>													

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 10-13, because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1 (iv):

Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers       , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers       , because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 90/00168**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on **90-08-28**.  
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4505906	85-03-19	BE-A- 901603	85-05-17
		CH-A-B- 668258	88-12-15
		FR-A-B- 2558829	85-08-02
		GB-A-B- 2153829	85-08-29
		JP-T- 61501088	86-05-29
		NL-T- 8420327	85-12-02
		WO-A- 85/03298	85-08-01
-----			
WO-A1- 8503939	85-09-12	AU-B- 584071	89-05-18
		AU-D- 3889585	85-09-24
		BE-A- 901879	85-07-01
		CH-A-B- 667658	88-10-31
		DE-T- 3590080	86-02-20
		FR-A-B- 2560597	85-09-06
		GB-A-B- 2155478	85-09-25
		JP-T- 61501447	86-07-17
		NL-T- 8520021	86-02-03
US-A- 4719204	88-01-12		